


Supplemental Material

Indication	MM	MM	MM	MM	MM	MM	MM	MM	MM	NHL	NHL	HD
Patient ID	1	2	3	4	6	7	9	11	8	5	10	12
Leukapheresis Day 1												
Pre-dose*	51	89	123	73	69	1	18	40	25	11	14	7
~1 h post-burixafor †	82	96	206	132	129	1	36	73	48	17	30	24
4 h post-burixafor	62	76	141	97	131	0	26	45	42	18	29	23
6 h post-burixafor	56	65	122	104	110	1	25	44	40	25	30	14
7-8 h post-burixafor ‡	51	83	89	109	119	3	30	31	40	22	30	13
Leukapheresis Day 2												
Pre-dose*						1	24	18	60	16	14	12
~1 h post-burixafor †						2	42	34	70	22	44	11
4 h post-burixafor						ND	26	32	45	14	30	26
6 h post-burixafor						ND	20	ND	45	0	31	15
7-8 h post-burixafor ‡						ND	24	18	45	16	31	16

Supplementary Figure 1

Engraftment following G-CSF plus burixafor-induced mobilization of CD34+ cells



sFig 1: Time (days) to engraftment for neutrophils (open square) and platelets (open circle) following HSCT with grafts mobilized using G-CSF and burixafor. Bars indicate mean $\pm$ standard deviation. Multiple Myeloma (n=9), non-Hodgkin Lymphoma (n=2), Hodgkin Disease (n=1).